BR112022024098A2 - Formulações e métodos para tratar a disfunção erétil - Google Patents

Formulações e métodos para tratar a disfunção erétil

Info

Publication number
BR112022024098A2
BR112022024098A2 BR112022024098A BR112022024098A BR112022024098A2 BR 112022024098 A2 BR112022024098 A2 BR 112022024098A2 BR 112022024098 A BR112022024098 A BR 112022024098A BR 112022024098 A BR112022024098 A BR 112022024098A BR 112022024098 A2 BR112022024098 A2 BR 112022024098A2
Authority
BR
Brazil
Prior art keywords
vardenafil
formulation
formulations
methods
erectile dysfunction
Prior art date
Application number
BR112022024098A
Other languages
English (en)
Portuguese (pt)
Inventor
Chow Moses
L Chow Sheryl
Original Assignee
Strategic Drug Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Strategic Drug Solutions Inc filed Critical Strategic Drug Solutions Inc
Publication of BR112022024098A2 publication Critical patent/BR112022024098A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022024098A 2020-05-26 2021-05-26 Formulações e métodos para tratar a disfunção erétil BR112022024098A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063029881P 2020-05-26 2020-05-26
PCT/US2021/034334 WO2021242913A1 (en) 2020-05-26 2021-05-26 Formulations and methods for treating erectile dysfunction

Publications (1)

Publication Number Publication Date
BR112022024098A2 true BR112022024098A2 (pt) 2023-02-07

Family

ID=78722740

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024098A BR112022024098A2 (pt) 2020-05-26 2021-05-26 Formulações e métodos para tratar a disfunção erétil

Country Status (10)

Country Link
US (1) US20240216383A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157449A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024521765A (cg-RX-API-DMAC7.html)
KR (1) KR20240013128A (cg-RX-API-DMAC7.html)
CN (1) CN116568289A (cg-RX-API-DMAC7.html)
AU (1) AU2021280285A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024098A2 (cg-RX-API-DMAC7.html)
CA (1) CA3179630A1 (cg-RX-API-DMAC7.html)
IL (1) IL298432A (cg-RX-API-DMAC7.html)
WO (2) WO2021242913A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL247528B1 (pl) * 2023-04-08 2025-07-21 Sativa Med Spolka Akcyjna Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3048501A (en) * 1999-11-18 2001-05-30 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
US20060207596A1 (en) * 2005-03-18 2006-09-21 Fairfield Clinical Trials, Llc Device and method for delivery of combination nasal medication
US8911751B2 (en) 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
MX2010004265A (es) * 2007-10-19 2010-07-28 Innozen Inc Composicion para administrar un ingrediente activo y metodo para hacer y usar el mismo.
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
US20140271847A1 (en) * 2013-03-13 2014-09-18 SatisPharma, LLC Formulations and methods for rapid penile erections
US20170014417A1 (en) * 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil
CN111655229A (zh) 2017-12-20 2020-09-11 卡里亚制药控股有限公司 包含伐地那非的薄膜制剂、其制备方法及其用途
CA3105187A1 (en) * 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs

Also Published As

Publication number Publication date
IL298432A (en) 2023-01-01
CA3179630A1 (en) 2021-12-02
CN116568289A (zh) 2023-08-08
JP2024521765A (ja) 2024-06-04
WO2021242913A1 (en) 2021-12-02
US20240216383A1 (en) 2024-07-04
EP4157449A4 (en) 2024-05-29
EP4157449A1 (en) 2023-04-05
WO2022250731A1 (en) 2022-12-01
AU2021280285A1 (en) 2023-02-02
KR20240013128A (ko) 2024-01-30

Similar Documents

Publication Publication Date Title
AR062556A1 (es) Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas
CU20190005A7 (es) Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico
ES2164767T3 (es) Formulaciones de propionato de fluticasona.
AR066405A1 (es) Vacuna
AR063201A1 (es) Composiciones farmaceuticas de ropinirol y metodos de uso de las mismas
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BR9913154A (pt) Composição de musse
PT1267832E (pt) Sistema auto-emulsionante de libertacao de farmaco
CR8850A (es) Composicion y metodo para tratar hemorroides y/o transtornos ano-rectales
MX362804B (es) Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor.
UY38055A (es) Composiciones oftálmicas de compuestos de bencimidazol para uso unico diario
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
CO2021005797A2 (es) Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia
BR112022011284A2 (pt) Composição tópica e métodos de medição da capacidade de resfriamento de uma composição tópica
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
AR031032A1 (es) Uso de la tolterodina en el tratamiento del asma
PT2465493E (pt) Composições tópicas para a prevenção e tratamento da irritação das células mucosas
AR036304A1 (es) Sistema nuevo de liberacion de droga autoemulsionable
BRPI0409413B8 (pt) composição farmacêutica, e, uso de um ácido ou sal biliar não conjugado
CL2021001397A1 (es) Vibegrón para el tratamiento de los síntomas de la vejiga hiperactiva
ES2195939T3 (es) Composicion para prevencion y/o tratamiento de trastornos circulatorios que comprende derivados de l-carnitina y extractos de ginkgo biloba.
ECSP088545A (es) Composición para prevenir o tratar daños de la mucosa en los conductos gastrointestinales
MX2022006712A (es) Metodo para el tratamiento de cancer utilizando celula adyuvante artificial (aavc).
AR066372A1 (es) Formulaciones de aminoacidos n-halogenados con compuestos antiinflamatorios

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: STRATEGIC DRUG SOLUTIONS, INC. (US)